VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in Vancouver with a focus on skin health and healthy aging, has announced the successful acquisition of an Applied Research and Development (ARD) grant in partnership with TransBIOtech based in Quebec.
This grant, awarded through the College and Community Innovation (CCI) program administered by the Natural Sciences and Engineering Council of Canada, in collaboration with the Social Sciences and Humanities Research Council and the Canadian Institutes of Health Research, amounts to $450,000 over a three-year period. It will specifically support Derm-Biome’s preclinical research initiatives, concentrating on inflammatory diseases and healthy aging.
Frédéric Couture, Principal Investigator and Head of Pharmaceutical Sciences at TransBIOtech, expressed enthusiasm about the collaboration: “This is very exciting news. We are delighted to extend our partnership with Derm-Biome and contribute to advancing their product pipeline towards new treatments. Together with co-PIs Dr. Sarah Paris-Robidas and Dr. Carole-Ann Huppé, our expertise in preclinical pharmacology will synergize with Derm-Biome’s scientific team to expedite future efficacy validations and facilitate crucial demonstrations necessary for upcoming clinical trial applications.”
Gordon Eberwein, CEO of Derm-Biome, also expressed satisfaction with the grant award: “We are thrilled to have received this Applied Research and Development grant and eagerly anticipate our ongoing collaboration with TransBIOtech as we advance our exciting preclinical pipeline.”
This collaboration underscores the commitment of both companies to pushing the boundaries of scientific research and development in pursuit of innovative treatments for inflammatory diseases and advancements in healthy aging.
